Arrowhead Research reported $-212.62M in EBITDA for its fiscal quarter ending in September of 2026.





Ebitda Change Date
Agios Pharmaceuticals USD -109.2M 540K Jun/2026
Alnylam Pharmaceuticals USD 360.27M 114.93M Sep/2026
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD -212.62M 64.94M Sep/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Incyte USD 778.57M 410.6M Jun/2026
Ionis Pharmaceuticals USD -95.22M 9.99M Sep/2026
Ligand Pharmaceuticals USD 74.27M 88.56M Jun/2026
Merck USD 1.42B 2.97B Jun/2026
Moderna USD -687M 571M Jun/2026
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Novartis USD 8.62B 2.14B Sep/2026
Sarepta Therapeutics USD -3.14M 33.31M Sep/2026
TG Therapeutics USD 89.8M 62.9M Sep/2026
Ultragenyx Pharmaceutical USD -61M 94M Jun/2026
Vertex Pharmaceuticals USD 888.6M 436.6M Sep/2026
Xencor USD 25.1M 59.73M Sep/2026